Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile
ConclusionsMSCs are a promising therapy for BPD, but they should be administered in early stages of the disease.
Source: Cytotherapy - Category: Cytology Source Type: research
More News: Babies | Bronchopulmonary Dysplasia | Cytology | Perinatology & Neonatology | Premature Birth